Cost-effectiveness of 15-valent or 20-valent pneumococcal conjugate vaccine for U.S. adults aged 65 years and older and adults 19 years and older with underlying conditions

In June 2021, the Advisory Committee on Immunization Practices (ACIP) recommended use of either 20-valent pneumococcal conjugate vaccine (PCV20) alone or 15-valent pneumococcal conjugate vaccine (PCV15) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all PCV-unvaccinated ad...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2025-01, Vol.44, p.126567, Article 126567
Hauptverfasser:	Rosenthal, Melissa, Stoecker, Charles, Leidner, Andrew J., Cho, Bo-Hyun, Pilishvili, Tamara, Kobayashi, Miwako
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adults Age Aged Aged, 80 and over Cerebrospinal fluid Cochlear implants Conjugates Cost analysis Cost effectiveness Cost-Benefit Analysis Disease Female Health care expenditures Humans Immunization Male Medicare Middle Aged Monte Carlo simulation Pediatrics Pneumococcal disease Pneumococcal Infections - economics Pneumococcal Infections - epidemiology Pneumococcal Infections - prevention & control Pneumococcal Vaccines - administration & dosage Pneumococcal Vaccines - economics Pneumococcal Vaccines - immunology Pneumonia Polysaccharides Quality-Adjusted Life Years Sensitivity analysis Transplants & implants United States - epidemiology Vaccination - economics Vaccination - methods Vaccinations Vaccines Vaccines, Conjugate - administration & dosage Vaccines, Conjugate - economics Vaccines, Conjugate - immunology Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!